(MedPage Today) — TORONTO — The antiviral agent valacyclovir demonstrated no benefit in early Alzheimer’s disease, the phase II VALAD trial showed.
On the primary outcome of change in Alzheimer’s Disease Assessment Scale-Cognitive subscale…
Source link : https://www.medpagetoday.com/meetingcoverage/aaic/116732
Author :
Publish date : 2025-07-29 21:15:00
Copyright for syndicated content belongs to the linked Source.
